



**SDI Review Form 1.6**

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	<b>Ms_JPRI_50964</b>
Title of the Manuscript:	<b>Multiple Sclerosis and Evaluation of Vitamin D Effect: A Review Study</b>
Type of the Article	

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ol style="list-style-type: none"> <li>1. The description of the disease is desirable in the following order: etiology, epidemiology, clinic, diagnosis, treatment.</li> <li>2. It is necessary to indicate the role of viral agents in the development of multiple sclerosis in the etiology.</li> <li>3. There are no references to the McDonald's criteria in the diagnosis.</li> <li>4. It is advisable to cite MR images</li> <li>5. The treatment does not indicate monoclonal antibodies against CD20+, interferon-beta, immunoglobulins.</li> </ol>	All the corrections have been done
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments		

**PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Are there ethical issues in this manuscript?</b>	(If yes, Kindly please write down the ethical issues here in details)	